AEterna Zentaris Company Profile (NASDAQ:AEZS)

About AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris logoAeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AEZS
  • CUSIP: N/A
  • Web: www.aezsinc.com
Capitalization:
  • Market Cap: $33.83 million
  • Outstanding Shares: 16,110,000
Average Prices:
  • 50 Day Moving Avg: $1.90
  • 200 Day Moving Avg: $1.88
  • 52 Week Range: $0.78 - $5.59
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.24
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $1.08 million
  • Price / Sales: 31.33
  • Book Value: $0.31 per share
  • Price / Book: 6.77
Profitability:
  • EBIDTA: ($27,360,000.00)
  • Net Margins: -1,945.78%
  • Return on Equity: -514.64%
  • Return on Assets: -85.79%
Debt:
  • Current Ratio: 3.70%
  • Quick Ratio: 3.70%
Misc:
  • Average Volume: 2.72 million shs.
  • Beta: 1.26
  • Short Ratio: 0.05
 

Frequently Asked Questions for AEterna Zentaris (NASDAQ:AEZS)

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) posted its earnings results on Thursday, August, 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.05. The firm earned $0.24 million during the quarter, compared to analyst estimates of $0.22 million. AEterna Zentaris had a negative net margin of 1,945.78% and a negative return on equity of 514.64%. The company's revenue for the quarter was up 153.1% on a year-over-year basis. View AEterna Zentaris' Earnings History.

When will AEterna Zentaris make its next earnings announcement?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for AEterna Zentaris.

Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2017?

3 equities research analysts have issued 12 month price objectives for AEterna Zentaris' shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate AEterna Zentaris' stock price to reach $4.33 in the next year. View Analyst Ratings for AEterna Zentaris.

What are analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:

  • 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (7/11/2017)
  • 2. Maxim Group analysts commented, "Summary Aeterna Zentaris announced its plan to file a new drug application (NDA) for Macrilen (macimorelin) for adults growth hormone deficiency (AGHD) in 3Q17, following its meeting with the FDA on March 29, 2017." (3/30/2017)

Are investors shorting AEterna Zentaris?

AEterna Zentaris saw a decline in short interest in the month of August. As of August 15th, there was short interest totalling 1,350,222 shares, a decline of 29.7% from the July 31st total of 1,920,407 shares. Based on an average daily volume of 1,360,977 shares, the days-to-cover ratio is currently 1.0 days. Currently, 13.7% of the shares of the company are short sold.

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:

  • David A. Dodd, Chairman of the Board
  • Michael Ward CPA, Chief Executive Officer
  • Dennis Turpin CA, Chief Financial Officer, Senior Vice President
  • Philip Allen Theodore, Senior Vice President, Chief Administrative Officer, General Counsel
  • Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
  • Jude Dinges, Chief Commercial Officer, Senior Vice President
  • Genevieve Lemaire, Chief Accounting Officer, Vice President - Finance
  • Michael Teifel, Vice President - Non-Clinical Sciences
  • Juergen H. L. Ernst, Lead Independent Director
  • Michael A. Cardiff, Director

How do I buy AEterna Zentaris stock?

Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEterna Zentaris stock can currently be purchased for approximately $2.10.


MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AEterna Zentaris (NASDAQ:AEZS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.33 (106.35% upside)

Analysts' Ratings History for AEterna Zentaris (NASDAQ:AEZS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Maxim GroupSet Price TargetBuy$4.00HighView Rating Details
7/5/2017HC WainwrightSet Price TargetBuy$3.00HighView Rating Details
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 -> $6.00N/AView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for AEterna Zentaris (NASDAQ:AEZS)
Earnings by Quarter for AEterna Zentaris (NASDAQ:AEZS)
Earnings History by Quarter for AEterna Zentaris (NASDAQ AEZS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017        
8/10/20176/30/2017($0.41)($0.46)$0.22 million$0.24 millionViewN/AView Earnings Details
5/8/20173/31/2017($0.33)($0.31)$0.85 million$0.26 millionViewListenView Earnings Details
3/15/201712/31/2016($0.73)($0.71)$0.40 million$0.30 millionViewN/AView Earnings Details
11/8/2016Q316($0.74)($0.61)$0.22 million$0.27 millionViewListenView Earnings Details
5/9/2016Q216($0.82)($0.71)$0.50 million$0.24 millionViewN/AView Earnings Details
3/29/2016Q415($1.30)($1.46)$0.25 million$0.10 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.07)$0.20 million$0.17 millionViewN/AView Earnings Details
8/13/2015Q215($0.08)($0.14)$0.55 million$0.20 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.10)($0.13)$0.07 millionViewN/AView Earnings Details
3/17/2015Q414($0.16)$0.06$0.01 millionViewN/AView Earnings Details
3/20/2014Q413($0.04)($0.22)$12.41 millionViewN/AView Earnings Details
3/21/2013Q412($0.31)($0.29)$7.96 million$9.16 millionViewN/AView Earnings Details
11/13/2012Q312($0.43)($0.35)$8.38 million$7.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AEterna Zentaris (NASDAQ:AEZS)
Current Year EPS Consensus Estimate: $-1.02 EPS
Next Year EPS Consensus Estimate: $-0.29 EPS

Dividends

Dividend History for AEterna Zentaris (NASDAQ:AEZS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for AEterna Zentaris (NASDAQ:AEZS)
Latest Headlines for AEterna Zentaris (NASDAQ:AEZS)
Source:
DateHeadline
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) Upgraded at ValuEngine
www.americanbankingnews.com - September 3 at 11:22 PM
streetinsider.com logoAeterna Zentaris (AEZS) VP, Finance & Chief Accounting Officer Departs - StreetInsider.com
www.streetinsider.com - September 3 at 1:31 AM
streetinsider.com logoAeterna Zentaris (AEZS) VP, Finance & Chief Accounting Officer Departs
www.streetinsider.com - September 2 at 2:14 AM
finance.yahoo.com logoAeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer
finance.yahoo.com - September 1 at 9:12 PM
americanbankingnews.com logoShort Interest in AEterna Zentaris Inc. (AEZS) Drops By 29.7%
www.americanbankingnews.com - August 29 at 1:06 AM
finance.yahoo.com logoÆterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 3:33 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: EnteroMedics and Aterna Zentaris
finance.yahoo.com - August 14 at 3:56 PM
americanbankingnews.com logoAEterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update
www.americanbankingnews.com - August 13 at 1:46 AM
finance.yahoo.com logoInvestor Network: Aeterna Zentaris Inc. to Host Earnings Call
finance.yahoo.com - August 11 at 4:01 PM
americanbankingnews.com logoMaxim Group Analysts Give AEterna Zentaris Inc. (AEZS) a $4.00 Price Target
www.americanbankingnews.com - August 11 at 1:26 PM
seekingalpha.com logoAeterna Zentaris Q2 beat propels shares, up 15% premarket
seekingalpha.com - August 11 at 8:55 AM
americanbankingnews.com logoAEterna Zentaris Inc. (NASDAQ:AEZS) Releases Earnings Results, Beats Estimates By $0.20 EPS
www.americanbankingnews.com - August 10 at 11:02 PM
businesswire.com logoAeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results - Business Wire (press release)
www.businesswire.com - August 10 at 10:00 PM
finance.yahoo.com logoAeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results
finance.yahoo.com - August 10 at 10:00 PM
finance.yahoo.com logoAeterna Zentaris reports 2Q loss
finance.yahoo.com - August 10 at 10:00 PM
streetinsider.com logoAeterna Zentaris (AEZS) Hires Financial Advisor to Review Alternatives
www.streetinsider.com - August 9 at 3:47 PM
streetinsider.com logoAeterna Zentaris (AEZS) Hires Financial Advisor to Review Alternatives - StreetInsider.com
www.streetinsider.com - August 9 at 1:44 AM
finance.yahoo.com logoAeterna Zentaris Engages Advisors and Provides Update to Shareholders
finance.yahoo.com - August 8 at 8:40 PM
americanbankingnews.com logoAEterna Zentaris Inc. (NASDAQ:AEZS) to Release Earnings on Thursday
www.americanbankingnews.com - August 7 at 10:48 AM
businesswire.com logoAeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017 - Business Wire (press release)
www.businesswire.com - August 4 at 8:47 PM
finance.yahoo.com logoAeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017
finance.yahoo.com - August 4 at 8:47 PM
seekingalpha.com logoAeterna Zentaris goes after former execs over alleged scheme to control company; shares up 14%
seekingalpha.com - August 4 at 11:39 AM
businesswire.com logoAeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore - Business Wire (press release)
www.businesswire.com - August 3 at 4:07 PM
finance.yahoo.com logoAeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore
finance.yahoo.com - August 3 at 4:07 PM
benzinga.com logoWall Street's M&A Chatter From July 25: Aeterna Zentaris, Rent-A-Center, Michael Kors-Jimmy Choo - Benzinga
www.benzinga.com - July 26 at 3:33 PM
finance.yahoo.com logoWill FDA Catalyst Put Aeterna Zentaris Shares Back on Track?
finance.yahoo.com - July 25 at 3:23 PM
finance.yahoo.com logoAEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions
finance.yahoo.com - July 24 at 1:43 PM
nasdaq.com logoAeterna Zentaris Forms Strategic Review Committee, Appoints Michael Ward As CEO
www.nasdaq.com - July 21 at 2:03 AM
streetinsider.com logoAfter-Hours Stock Movers 07/20: (AEZS) (ATHN) (MSFT) Higher; (MANH) (NCR) (MXIM) Lower (more...)
www.streetinsider.com - July 20 at 9:03 PM
finance.yahoo.com logoAeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO
finance.yahoo.com - July 20 at 9:02 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Sears, Sarepta Qualcomm, A Schulman - Nasdaq
www.nasdaq.com - July 20 at 4:01 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Vertex Pharmaceuticals and Aeterna Zentaris
finance.yahoo.com - July 20 at 4:01 PM
finanznachrichten.de logoGainers & Losers Of July 19: AEZS, VRTX, AGRX, PTI, INO...
www.finanznachrichten.de - July 20 at 2:39 AM
baystreet.ca logoDrug Company More than Doubles in Price on FDA Notification
www.baystreet.ca - July 19 at 4:36 PM
benzinga.com logoMid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide - Benzinga
www.benzinga.com - July 19 at 4:26 PM
marketwatch.com logoAEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling - MarketWatch
www.marketwatch.com - July 19 at 4:26 PM
finance.yahoo.com logoAEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling
finance.yahoo.com - July 19 at 4:26 PM
americanbankingnews.com logoAEterna Zentaris Inc. (NASDAQ:AEZS) Price Target Raised to $4.00
www.americanbankingnews.com - July 19 at 1:56 PM
rttnews.com logoFDA Nod For GILD, It's Take 2 For AEZS' Macrilen, VRTX Soars On CF Drug Trials
www.rttnews.com - July 19 at 2:29 AM
streetinsider.com logoAfter-Hours Stock Movers 07/18: (AEZS) (VRTX) (EXPO) Higher; (DRYS) (HDP) (IBM) (CSX) (UAL) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 18 at 9:28 PM
streetinsider.com logoAeterna Zentaris (AEZS) Granted 12/30/17 PDUFA Date for Macrilen NDA Approval - StreetInsider.com
www.streetinsider.com - July 18 at 9:28 PM
finance.yahoo.com logoNDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
finance.yahoo.com - July 18 at 9:28 PM
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 6:02 PM
americanbankingnews.com logoBrokerages Expect AEterna Zentaris Inc. (AEZS) to Post ($0.41) EPS
www.americanbankingnews.com - July 10 at 2:30 PM
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) PT Set at $3.00 by HC Wainwright
www.americanbankingnews.com - July 9 at 6:02 PM
zacks.com logoDo Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't?
www.zacks.com - July 8 at 8:33 PM
nasdaq.com logoDo Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't? - Nasdaq
www.nasdaq.com - July 7 at 5:23 PM
finance.yahoo.com logoDo Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't?
finance.yahoo.com - July 7 at 5:23 PM
americanbankingnews.com logoMaxim Group Analysts Give AEterna Zentaris Inc. (AEZS) a $2.00 Price Target
www.americanbankingnews.com - July 3 at 6:25 PM
streetinsider.com logoAeterna Zentaris (AEZS) Resubmits NDA for Macrilen for Evaluation of AGHD
www.streetinsider.com - June 30 at 8:41 PM

Social

Chart

AEterna Zentaris (AEZS) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff